secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2024-09-11T23:59:59+00:00
Accession:  0001193125-24-217302
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics appoints Meg Alexander as President and COO effective Sept 9
------------------------------------------------------------------------------

- Annual base salary of $500,000; target bonus of 45% of base salary.
- Granted option to purchase 140,000 shares at $1.07 per share, 10-year term.
- Option vests 25% on one-year anniversary, then monthly over 36 months.
- Severance includes 12 months salary and COBRA gross-up on covered termination.
- Alexander previously served as Chief Strategy Officer since June 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000119312524217302/0001193125-24-217302-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000119312524217302/d869021d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-217302

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer